These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 20870728)
1. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. Oliva CR; Nozell SE; Diers A; McClugage SG; Sarkaria JN; Markert JM; Darley-Usmar VM; Bailey SM; Gillespie GY; Landar A; Griguer CE J Biol Chem; 2010 Dec; 285(51):39759-67. PubMed ID: 20870728 [TBL] [Abstract][Full Text] [Related]
2. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. Oliva CR; Moellering DR; Gillespie GY; Griguer CE PLoS One; 2011; 6(9):e24665. PubMed ID: 21931801 [TBL] [Abstract][Full Text] [Related]
3. Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Gielen PR; Aftab Q; Ma N; Chen VC; Hong X; Lozinsky S; Naus CC; Sin WC Neuropharmacology; 2013 Dec; 75():539-48. PubMed ID: 23688923 [TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
5. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257 [TBL] [Abstract][Full Text] [Related]
7. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide. Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167 [TBL] [Abstract][Full Text] [Related]
8. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
9. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen. Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781 [TBL] [Abstract][Full Text] [Related]
10. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma. Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873 [No Abstract] [Full Text] [Related]
11. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells. Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389 [TBL] [Abstract][Full Text] [Related]
12. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity. Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595 [TBL] [Abstract][Full Text] [Related]
13. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319 [TBL] [Abstract][Full Text] [Related]
14. FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling. Lu C; Cui C; Liu B; Zou S; Song H; Tian H; Zhao J; Li Y Neurosci Lett; 2017 Sep; 657():77-83. PubMed ID: 28778805 [TBL] [Abstract][Full Text] [Related]
15. LncRNA-XIST interacts with Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma. Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044 [TBL] [Abstract][Full Text] [Related]
17. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species. Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068 [TBL] [Abstract][Full Text] [Related]
18. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
20. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]